ELSEVIER

Journal of Affective Disorders 47 (1997) 215–216

JOURNAL OF AFFECTIVE DISORDERS

Author index

Agosti, V. and Stewart, J.W.
Social functioning and residual symptomatology among outpatients who responded to treatment and recovered from major depression (47) 207
Akiskal, H.S., see Perugi, G. (47) 11
Akiskal, H.S., see Placidi, G.F. (47) 1
Alexander, P.E., see Uhlenhuth, E.H. (47) 183
Ambrumova, A., see Polyakova, I. (47) 159
Amsterdam, J.D., García-España, F. and Rybakowski, J.
Rates of flu-like infection in patients with affective illness (47) 177
Austin, M.-P., see Parker, G. (47) 131

Benedetti, A., see Perugi, G. (47) 11
Biederman, J., Mick, E. and Faraone, S.V.
Depression in attention deficit hyperactivity disorder (ADHD) children: "True" depression or demoralization? (47) 113
Bo Mortensen, P., see Kessing, L.V. (47) 31
Bo Mortensen, P., see Kessing, L.V. (47) 41
Bolwig, T.G., see Kessing, L.V. (47) 31
Bolwig, T.G., see Kessing, L.V. (47) 41
Bouhuys, A.L., see Hale III, W.W. (47) 63
Buesching, D.P., see Hylan, T.R. (47) 71

Chao, A., see Yip, P.S.F. (47) 141
Coleman, B.S., see Uhlenhuth, E.H. (47) 183
Cox, B.J., see Enns, M.W. (47) 195
Croghan, T.W., see Hylan, T.R. (47) 71
Crompton, M.R., see Lawrence, K.M. (47) 105
Crown, W.H., see Hylan, T.R. (47) 71

Deakin, B., see Strickland, P. (47) 191
Dempsey, G.M., see Uhlenhuth, E.H. (47) 183
Dinan, T.G., see Scott, L.V. (47) 49
Duggan, C., Sham, P., Minne, C., Lee, A. and Murray, R.
Does the method of data collection affect the reporting of depression in the relatives of depressed probands? (47) 151

Echlin, D., see Hawley, C.J. (47) 87
Enns, M.W., Cox, B.J., Parker, J.D.A. and Guertin, J.E.
Confirmatory factor analysis of the Beck Anxiety and Depression Inventories in patients with major depression (47) 195
Entsuah, A.R., see Feighner, J.P. (47) 55

Faraone, S.V., see Biederman, J. (47) 113
Feighner, J.P., Entsuah, A.R. and McPherson, M.K.
Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients (47) 55
Fujikawa, T., see Yanai, I. (47) 25

García-España, F., see Amsterdam, J.D. (47) 177
Gayant, C., see Loas, G. (47) 81
Gervasi, R., see Placidi, G.F. (47) 1
Guelfi, J.D., see Loas, G. (47) 81
Guertin, J.E., see Enns, M.W. (47) 195

Hadzi-Pavlovic, D., see Parker, G. (47) 131
Hale III, W.W., Jansen, J.H.C., Bouhuys, A.L. and van den Hoofdakker, R.H.
The judgment of facial expressions by depressed patients, their partners and controls (47) 63
Hawley, C.J., Pattinson, H.A., Quick, S.J., Echlin, D., Smith, V., McPhee, S. and Sivakumaran, T.
A protocol for the pharmacologic treatment of major depression. A field test of a potential prototype (47) 87
Heiligenstein, J.H., see Hylan, T.R. (47) 71
Ho, T.P., see Yip, P.S.F. (47) 141
Horiguchi, J., see Yanai, I. (47) 25
Horton, R.W., see Lawrence, K.M. (47) 105
Hylan, T.R., Crown, W.H., Meneades, L., Heiligenstein, J.H., Melfi, C.A., Croghan, T.W. and Buesching, D.P.
Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis (47) 71

Jansen, J.H.C., see Hale III, W.W. (47) 63
Joffe, R.T., see Levitt, A.J. (47) 169
Jones, W., see Uhlenhuth, E.H. (47) 183

Kanagasundaram, M., see Lawrence, K.M. (47) 105
Katona, C.L.E., see Lawrence, K.M. (47) 105
Kemper, B., see Kuhs, H. (47) 97
Kessing, L.V., Bo Mortensen, P. and Bolwig, T.G.
Clinical definitions of sensitisation in affective disorder a case register study of prevalence and prediction (47) 31
Kessing, L.V., Bo Mortensen, P. and Bolwig, T.B.

S0165-0327(97)00186-9

Clinical consequences of sensitisation in affective disorder. A case register study (47) 41
Knobler, H.Y., see Polyakova, I. (47) 159
Kueneman, K., see Sharma, V. (47) 123
Kuhs, H., Kemper, B., Lippe-Neubauer, U., Meyer-Dunker, J. and Tölle, R.
Repeated sleep deprivation once versus twice a week in combination with amitriptyline (47) 97

Lawrence, K.M., Kanagasundaram, M., Lowther, S., Katona, C.L.E., Crompton, M.R. and Horton, R.W.
[^{3}H] Imipramine binding in brain samples from depressed suicides and controls: 5-HT uptake sites compared with sites defined by desmethylimipramine (47) 105
Lee, A., see Duggan, C. (47) 151
Lerner, V., see Polyakova, I. (47) 159
Levitt, A.J., Joffe, R.T. and Sokolov, S.T.H.
Does the chronological relationship between the onset of dysthymia and major depression influence subsequent response to antidepressants? (47) 169
Liguori, A., see Placidi, G.F. (47) 1
Lippe-Neubauer, U., see Kuhs, H. (47) 97
Loas, G., Verrier, A., Gayant, C. and Guelfi, J.D.
Depression and dependency: distinct or overlapping constructs? (47) 81
Lowther, S., see Lawrence, K.M. (47) 105

Maremmani, I., see Placidi, G.F. (47) 1
McPhee, S., see Hawley, C.J. (47) 87
McPherson, M.K., see Feighner, J.P. (47) 55
Melfi, C.A., see Hylan, T.R. (47) 71
Meneades, L., see Hylan, T.R. (47) 71
Meyer-Dunker, J., see Kuhs, H. (47) 97
Mick, E., see Biederman, J. (47) 113
Minne, C., see Duggan, C. (47) 151
Mitchell, P., see Parker, G. (47) 131
Morriss, R., see Strickland, P. (47) 191
Murray, R., see Duggan, C. (47) 151
Musetti, L., see Perugi, G. (47) 11

Parker, G., Roussos, J., Austin, M.-P., Hadzi-Pavlovic, D., Wilhelm, K. and Mitchell, P.
Disordered personality style: higher rates in non-melancholic compared to melancholic depression (47) 131
Parker, J.D.A., see Enns, M.W. (47) 195
Pattinson, H.A., see Hawley, C.J. (47) 87
Persad, E., see Sharma, V. (47) 123
Perugi, G., Toni, C., Benedetti, A., Simonetti, B., Simoncini, M., Torti, C., Musetti, L. and Akiskal, H.S.
Delineating a putative phobic-anxious temperament in 126 panic-agoraphobic patients: toward a rapprochement of European and US views (47) 11
Placidi, G.F., Signoretta, S., Liguori, A., Gervasi, R., Maremmani, I. and Akiskal, H.S.
The semi-structured affective temperament interview (TEMPS-I). Reliability and psychometric properties in 1010 14–26-year-old students (47) 1
Polyakova, I., Knobler, H.Y., Ambrumova, A. and Lerner, V.
Characteristics of suicidal attempts in major depression versus adjustment reactions (47) 159

Quick, S.J., see Hawley, C.J. (47) 87

Roussos, J., see Parker, G. (47) 131
Rybakowski, J., see Amsterdam, J.D. (47) 177

Schneider, A.L. and Wilcox, C.S.
Divalproate augmentation in lithium-resistant rapid cycling mania in four geriatric patients (47) 201
Scott, L.V. and Dinan, T.G.
Urinary free cortisol excretion in chronic fatigue syndrome, major depression and in healthy volunteers (47) 49
Sham, P., see Duggan, C. (47) 151
Sharma, V., Persad, E. and Kueneman, K.
A closer look at inpatient suicide (47) 123
Signoretta, S., see Placidi, G.F. (47) 1
Simoncini, M., see Perugi, G. (47) 11
Simonetti, B., see Perugi, G. (47) 11
Sivakumaran, T., see Hawley, C.J. (47) 87
Smith, V., see Hawley, C.J. (47) 87
Sokolov, S.T.H., see Levitt, A.J. (47) 169
Stewart, J.W., see Agosti, V. (47) 207
Strickland, P., Morriss, R., Wearden, A. and Deakin, B.
A comparison of salivary cortisol in chronic fatigue syndrome, community depression and healthy controls (47) 191
Swiontek, A.M., see Uhlenhuth, E.H. (47) 183

Tölle, R., see Kuhs, H. (47) 97
Toni, C., see Perugi, G. (47) 11
Torti, C., see Perugi, G. (47) 11
Touhouda, Y., see Yanai, I. (47) 25

Uhlenhuth, E.H., Alexander, P.E., Dempsey, G.M., Jones, W., Coleman, B.S. and Swiontek, A.M.
Medication side effects in anxious patients: Negative placebo responses? (47) 183

van den Hoofdakker, R.H., see Hale III, W.W. (47) 63
Verrier, A., see Loas, G. (47) 81

Wearden, A., see Strickland, P. (47) 191
Wilcox, C.S., see Schneider, A.L. (47) 201
Wilhelm, K., see Parker, G. (47) 131

Yamawaki, S., see Yanai, I. (47) 25
Yanai, I., Fujikawa, T., Horiguchi, J., Yamawaki, S. and Touhouda, Y.
The 3-year course and outcome of patients with major depression and silent cerebral infarction (47) 25
Yip, P.S.F., Chao, A. and Ho, T.P.
A re-examination of seasonal variation in suicides in Australia and New Zealand (47) 141

ELSEVIER

Journal of Affective Disorders 47 (1997) 217–219

JOURNAL OF AFFECTIVE DISORDERS

Subject index

ADHD; Major Depression; Comorbidity; Remission; Persistence **47,** 113

Adjustment reaction; Major depression; Suicidal attempt **47,** 159

Affective disorder; Case register; Sensitisation; Course **47,** 31

Affective disorder; Case register; Sensitisation; Alcohol; Dementia; Suicide **47,** 41

Affective disorders; Viral infections; Anti-viral; Psychotropic drugs; Lithium **47,** 177

Affective temperaments; Cyclothymic; Depressive; Hyperthymic; Irritable **47,** 1

Agoraphobia; Panic disorder; Phobic-anxious temperament; Hypersensitivity to separation; Prodromal symptoms **47,** 11

Alcohol; Affective disorder; Case register; Sensitisation; Dementia; Suicide **47,** 41

Antidepressant drugs; Suicide; Depression; [^{3}H]imipramine binding sites; Post-mortem brain tissue; Frontal cortex; Putamen; Substantia nigra **47,** 105

Antidepressants; Depression; Dysthymia; Double depression **47,** 169

Anti-viral; Viral infections; Psychotropic drugs; Lithium; Affective disorders **47,** 177

Anxiety; Major depression; Venlafaxine; Extended-release **47,** 55

Anxiety; Depression; Measurement; Confirmatory factor analysis **47,** 195

Anxiety disorders; Negative placebo response; Somatization; Extended release alprazolam **47,** 183

Case register; Affective disorder; Sensitisation; Course **47,** 31

Case register; Affective disorder; Sensitisation; Alcohol; Dementia; Suicide **47,** 41

Cerebral infarction; Depression; Dementia; Magnetic resonance imaging **47,** 25

Chronic fatigue syndrome (CFS); Depression; Urinary free cortisol (UFC); Hypothalamic-pituitary-adrenal (HPA) axis **47,** 49

Chronic fatigue syndrome; Depression; Cortisol; Saliva **47,** 191

Combined pharmacotherapy and sleep deprivation; Major depressive episode; Partial sleep deprivation; Repeated sleep deprivartion; Sleep deprivation interval **47,** 97

Comorbidity; Major Depression; ADHD; Remission; Persistence **47,** 113

Compliance; Depression; Lithium; Lofepramine; Paroxetine; Protocol **47,** 87

Confirmatory factor analysis; Depression; Anxiety; Measurement **47,** 195

Cortisol; Chronic fatigue syndrome; Depression; Saliva **47,** 191

Course; Affective disorder; Case register; Sensitisation **47,** 31

Cyclothymic; Affective temperaments; Depressive; Hyperthymic; Irritable **47,** 1

Dementia; Depression; Cerebral infarction; Magnetic resonance imaging **47,** 25

Dementia; Affective disorder; Case register; Sensitisation; Alcohol; Suicide **47,** 41

Dependency; Depression; Factor analysis **47,** 81

Depression; Dementia; Cerebral infarction; Magnetic resonance imaging **47,** 25

Depression; Chronic fatigue syndrome (CFS); Urinary free cortisol (UFC); Hypothalamic-pituitary-adrenal (HPA) axis **47,** 49

Depression; Facial expression; Face; Judgment of emotions; Depression severity **47,** 63

Depression; Health care costs; Selective serotonin reuptake inhibitors; Tricyclic antidepressants **47,** 71

Depression; Dependency; Factor analysis **47,** 81

Depression; Compliance; Lithium; Lofepramine; Paroxetine; Protocol **47,** 87

Depression; Suicide; [^{3}H]imipramine binding sites; Post-mortem brain tissue; Antidepressant drugs; Frontal cortex; Putamen; Substantia nigra **47,** 105

Depression; Mood disorder; Personality; Melancholic and non-melancholic depression; Sub-typing **47,** 131

Depression; Dysthymia; Antidepressants; Double depression **47,** 169

S0165-0327(97)00187-0

Depression; Chronic fatigue syndrome; Cortisol; Saliva **47,** 191

Depression; Anxiety; Measurement; Confirmatory factor analysis **47,** 195

Depression severity; Depression; Facial expression; Face; Judgment of emotions **47,** 63

Depressive; Affective temperaments; Cyclothymic; Hyperthymic; Irritable **47,** 1

Double depression; Depression; Dysthymia; Antidepressants **47,** 169

Dysthymia; Depression; Antidepressants; Double depression **47,** 169

Extended release alprazolam; Anxiety disorders; Negative placebo response; Somatization **47,** 183

Extended-release; Major depression; Anxiety; Venlafaxine **47,** 55

Face; Depression; Facial expression; Judgment of emotions; Depression severity **47,** 63

Facial expression; Depression; Face; Judgment of emotions; Depression severity **47,** 63

Factor analysis; Depression; Dependency **47,** 81

Family studies; Major depression; Genetics **47,** 151

Frontal cortex; Suicide; Depression; [^{3}H]imipramine binding sites; Post-mortem brain tissue; Antidepressant drugs; Putamen; Substantia nigra **47,** 105

Genetics; Major depression; Family studies **47,** 151

Harmonic analysis; Seasonal variation; Suicides **47,** 141

Health care costs; Selective serotonin reuptake inhibitors; Tricyclic antidepressants; Depression **47,** 71

Hypersensitivity to separation; Panic disorder; Agoraphobia; Phobic-anxious temperament; Prodromal symptoms **47,** 11

Hyperthymic; Affective temperaments; Cyclothymic; Depressive; Irritable **47,** 1

Hypothalamic-pituitary-adrenal (HPA) axis; Chronic fatigue syndrome (CFS); Depression; Urinary free cortisol (UFC) **47,** 49

[^{3}H]imipramine binding sites; Suicide; Depression; Post-mortem brain tissue; Antidepressant drugs; Frontal cortex; Putamen; Substantia nigra **47,** 105

Inpatients; Suicide; Mood disorders; Mood cycling **47,** 123

Irritable; Affective temperaments; Cyclothymic; Depressive; Hyperthymic **47,** 1

Judgment of emotions; Depression; Facial expression; Face; Depression severity **47,** 63

Lithium; Compliance; Depression; Lofepramine; Paroxetine; Protocol **47,** 87

Lithium; Viral infections; Anti-viral; Psychotropic drugs; Affective disorders **47,** 177

Lofepramine; Compliance; Depression; Lithium; Paroxetine; Protocol **47,** 87

Magnetic resonance imaging; Depression; Dementia; Cerebral infarction **47,** 25

Major depression; Anxiety; Venlafaxine; Extended-release **47,** 55

Major Depression; ADHD; Comorbidity; Remission; Persistence **47,** 113

Major depression; Genetics; Family studies **47,** 151

Major depression; Adjustment reaction; Suicidal attempt **47,** 159

Major depression; Recovery; Normality **47,** 207

Major depressive episode; Partial sleep deprivation; Repeated sleep deprivartion; Combined pharmacotherapy and sleep deprivation; Sleep deprivation interval **47,** 97

Measurement; Depression; Anxiety; Confirmatory factor analysis **47,** 195

Melancholic and non-melancholic depression; Mood disorder; Depression; Personality; Sub-typing **47,** 131

Mood cycling; Suicide; Mood disorders; Inpatients **47,** 123

Mood disorder; Depression; Personality; Melancholic and non-melancholic depression; Sub-typing **47,** 131

Mood disorders; Suicide; Mood cycling; Inpatients **47,** 123

Negative placebo response; Anxiety disorders; Somatization; Extended release alprazolam **47,** 183

Normality; Major depression; Recovery **47,** 207

Panic disorder; Agoraphobia; Phobic-anxious temperament; Hypersensitivity to separation; Prodromal symptoms **47,** 11

Paroxetine; Compliance; Depression; Lithium; Lofepramine; Protocol **47,** 87

Partial sleep deprivation; Major depressive episode; Repeated sleep deprivartion; Combined pharmacotherapy and sleep deprivation; Sleep deprivation interval **47,** 97

Persistence; Major Depression; ADHD; Comorbidity; Remission **47,** 113

Personality; Mood disorder; Depression; Melancholic and non-melancholic depression; Sub-typing **47,** 131

Phobic-anxious temperament; Panic disorder; Agoraphobia; Hypersensitivity to separation; Prodromal symptoms **47,** 11

Post-mortem brain tissue; Suicide; Depression; [^{3}H]imipramine binding sites; Antidepressant drugs; Frontal cortex; Putamen; Substantia nigra **47,** 105

Prodromal symptoms; Panic disorder; Agoraphobia; Phobic-anxious temperament; Hypersensitivity to separation **47,** 11

Protocol; Compliance; Depression; Lithium; Lofepramine; Paroxetine **47,** 87

Psychotropic drugs; Viral infections; Anti-viral; Lithium; Affective disorders **47,** 177

Putamen; Suicide; Depression; [^{3}H]imipramine binding sites; Post-mortem brain tissue; Antidepressant drugs; Frontal cortex; Substantia nigra **47,** 105

Recovery; Major depression; Normality **47,** 207

Remission; Major Depression; ADHD; Comorbidity; Persistence **47,** 113

Repeated sleep deprivartion; Major depressive episode; Partial sleep deprivation; Combined pharmacotherapy and sleep deprivation; Sleep deprivation interval **47,** 97

Saliva; Chronic fatigue syndrome; Depression; Cortisol **47,** 191

Seasonal variation; Harmonic analysis; Suicides **47,** 141

Selective serotonin reuptake inhibitors; Health care costs; Tricyclic antidepressants; Depression **47,** 71

Sensitisation; Affective disorder; Case register; Course **47,** 31

Sensitisation; Affective disorder; Case register; Alcohol; Dementia; Suicide **47,** 41

Sleep deprivation interval; Major depressive episode; Partial sleep deprivation; Repeated sleep deprivartion; Combined pharmacotherapy and sleep deprivation **47,** 97

Somatization; Anxiety disorders; Negative placebo response; Extended release alprazolam **47,** 183

Substantia nigra; Suicide; Depression; [^{3}H]imipramine binding sites; Post-mortem brain tissue; Antidepressant drugs; Frontal cortex; Putamen **47,** 105

Sub-typing; Mood disorder; Depression; Personality; Melancholic and non-melancholic depression **47,** 131

Suicidal attempt; Major depression; Adjustment reaction **47,** 159

Suicide; Affective disorder; Case register; Sensitisation; Alcohol; Dementia **47,** 41

Suicide; Depression; [^{3}H]imipramine binding sites; Post-mortem brain tissue; Antidepressant drugs; Frontal cortex; Putamen; Substantia nigra **47,** 105

Suicide; Mood disorders; Mood cycling; Inpatients **47,** 123

Suicides; Harmonic analysis; Seasonal variation **47,** 141

Tricyclic antidepressants; Health care costs; Selective serotonin reuptake inhibitors; Depression **47,** 71

Urinary free cortisol (UFC); Chronic fatigue syndrome (CFS); Depression; Hypothalamic-pituitary-adrenal (HPA) axis **47,** 49

Venlafaxine; Major depression; Anxiety; Extended-release **47,** 55

Viral infections; Anti-viral; Psychotropic drugs; Lithium; Affective disorders **47,** 177